Dynasty Wealth Management LLC increased its position in Eli Lilly and Company (NYSE:LLY – Free Report) by 235.9% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 3,104 shares of the company’s stock after purchasing an additional 2,180 shares during the quarter. Dynasty Wealth Management LLC’s holdings in Eli Lilly and Company were worth $3,336,000 as of its most recent filing with the Securities & Exchange Commission.
Other institutional investors and hedge funds also recently made changes to their positions in the company. Maryland Capital Advisors Inc. purchased a new position in shares of Eli Lilly and Company in the 4th quarter valued at approximately $25,000. Miller Global Investments LLC purchased a new position in shares of Eli Lilly and Company in the 4th quarter valued at approximately $33,000. E Fund Management Hong Kong Co. Ltd. lifted its stake in shares of Eli Lilly and Company by 342.9% in the 4th quarter. E Fund Management Hong Kong Co. Ltd. now owns 31 shares of the company’s stock valued at $32,000 after purchasing an additional 24 shares during the period. Dorato Capital Management purchased a new position in shares of Eli Lilly and Company in the 4th quarter valued at approximately $36,000. Finally, New England Capital Financial Advisors LLC lifted its stake in shares of Eli Lilly and Company by 142.9% in the 4th quarter. New England Capital Financial Advisors LLC now owns 34 shares of the company’s stock valued at $37,000 after purchasing an additional 20 shares during the period. Hedge funds and other institutional investors own 82.53% of the company’s stock.
Eli Lilly and Company News Roundup
Here are the key news stories impacting Eli Lilly and Company this week:
- Positive Sentiment: CVS Caremark has expanded coverage of Eli Lilly’s full obesity portfolio, including the newly approved oral therapy Foundayo and Zepbound, meaning all three of the largest U.S. pharmacy benefit managers now cover Lilly’s obesity medicines. That broadens access for millions of patients and strengthens the commercial case for Lilly’s GLP-1 franchise. Article Title
- Positive Sentiment: Lilly also announced new and expanding drug-development partnerships in Asia, including licensing deals with Hanmi and Haisco, which add to its pipeline and could create future revenue opportunities. Article Title
- Positive Sentiment: Positive Phase 3 results for Retevmo in lung cancer and upcoming hematology presentations at the EHA meeting suggest Lilly continues to build value in its non-obesity portfolio as well. Article Title
- Neutral Sentiment: Several commentary pieces highlighted Lilly as a top stock and pointed to strong CEO remarks and “Nvidia-like” growth, which may support sentiment but do not change fundamentals on their own. Article Title
- Neutral Sentiment: Some articles note competitive pressure in the GLP-1 market, including Viking Therapeutics’ upcoming catalyst and Novo Nordisk’s continued lead in the oral weight-loss pill race, but these are more watch items than immediate threats. Article Title
- Negative Sentiment: One ETF-focused article argued investors should avoid a pharmaceutical fund despite Lilly’s strength because the rest of the holdings are less attractive; this is not a direct negative for Lilly, but it reflects that some market commentary is more cautious on the broader pharma trade. Article Title
Eli Lilly and Company Stock Down 1.6%
Eli Lilly and Company (NYSE:LLY – Get Free Report) last posted its quarterly earnings results on Thursday, April 30th. The company reported $8.55 earnings per share for the quarter, topping the consensus estimate of $6.97 by $1.58. Eli Lilly and Company had a return on equity of 105.77% and a net margin of 34.98%.The firm had revenue of $19.80 billion during the quarter, compared to analysts’ expectations of $17.82 billion. During the same quarter in the previous year, the business earned $3.34 earnings per share. The company’s revenue was up 55.5% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. Equities analysts forecast that Eli Lilly and Company will post 35.8 earnings per share for the current fiscal year.
Eli Lilly and Company Dividend Announcement
The firm also recently declared a quarterly dividend, which will be paid on Wednesday, June 10th. Stockholders of record on Friday, May 15th will be paid a $1.73 dividend. The ex-dividend date is Friday, May 15th. This represents a $6.92 annualized dividend and a dividend yield of 0.7%. Eli Lilly and Company’s payout ratio is currently 24.58%.
Analyst Ratings Changes
A number of research firms have recently commented on LLY. Rothschild & Co Redburn raised their target price on Eli Lilly and Company from $880.00 to $900.00 in a research note on Thursday, May 7th. Loop Capital set a $1,200.00 target price on Eli Lilly and Company in a research note on Tuesday, February 10th. Deutsche Bank Aktiengesellschaft restated a “buy” rating and issued a $1,285.00 target price on shares of Eli Lilly and Company in a research note on Friday, March 6th. The Goldman Sachs Group reiterated a “buy” rating and set a $1,283.00 price objective on shares of Eli Lilly and Company in a research note on Friday, May 22nd. Finally, Wall Street Zen upgraded Eli Lilly and Company from a “buy” rating to a “strong-buy” rating in a research note on Saturday, May 2nd. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Eli Lilly and Company has a consensus rating of “Moderate Buy” and an average price target of $1,227.00.
Get Our Latest Stock Analysis on LLY
Eli Lilly and Company Profile
Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.
Featured Stories
- Five stocks we like better than Eli Lilly and Company
- Marvell Stock Soars on NVIDIA’s Trillion-Dollar Nod
- FirstCash Turns Pawn Into a Growth Machine
- HubSpot Just Crushed the Bear Case—Is a Bigger Rally Ahead?
- Aggressive Insider Buying Signals Opportunity in 3 Risky Stocks
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY – Free Report).
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.
